Juliette Audet is Partner in the Naarden office and joined the Forbion team in 2019. She currently serves as a board member for NewAmsterdam Pharma. Prior to joining Forbion, Juliette was a Principal at Novartis Venture Fund based in Cambridge (USA). There she sat on the boards of TScan Therapeutics and Annexon Biosciences as an observer. Juliette was also leading the management of NVF’s public equities. Before that, Juliette was a Senior Manager of Strategy at Novartis AG, where she worked with the senior executive team of the Pharma division. Juliette spent the first 4 years of her career in management consulting at McKinsey and Company focusing on Pharma and Biotech, based out of the Swiss and then New York offices. Juliette graduated with distinction from Harvard Business School in 2015 (MBA) and received her MSc in Physics (Suma Cum Laude) from EPFL (Lausanne, Swiss Federal Institute of Technology) in 2010.